108038-52-4

Basic information

• Product Name: 5-BENZIMIDAZOLECARBOXYLIC ACID, HYDRAZIDE
• Synonyms: 5-BENZIMIDAZOLECARBOXYLIC ACID, HYDRAZIDE;5-Benzimidazolecarboxylicacid,hydrazide(6CI);1H-BenziMidazole-6-carboxylic acid, hydrazide;1H-Benzimidazole-5-carbohydrazide;1H-Benzoimidazole-5-carboxylic acid hydrazide
• CAS NO: 108038-52-4
• Molecular Formula: C₈H₈N₄O
• Molecular Weight: 176.17532
• Product Categories: BENZIMIDAZOLE
• Mol File: 108038-52-4.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-BENZIMIDAZOLECARBOXYLIC ACID, HYDRAZIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BENZIMIDAZOLECARBOXYLIC ACID, HYDRAZIDE(108038-52-4)
• EPA Substance Registry System: 5-BENZIMIDAZOLECARBOXYLIC ACID, HYDRAZIDE(108038-52-4)

Safety Data

• Hazardous Substances Data: 108038-52-4(Hazardous Substances Data)

Usage

Description

5-Benzimidazolecarboxylic Acid, Hydrazide is a chemical compound with the molecular formula C8H8N4O2 and a molecular weight of 178.18 g/mol. It is a pharmaceutical intermediate that appears in crystalline or powder form and is primarily used in research settings for the production of pharmaceuticals. Due to its hazardous nature, it requires careful handling and storage in compliance with local environmental regulations.

Uses

Used in Pharmaceutical Industry:
5-Benzimidazolecarboxylic Acid, Hydrazide is used as a pharmaceutical intermediate for the production of various pharmaceuticals. Its application in this industry is due to its potential role in the synthesis of active pharmaceutical ingredients, contributing to the development of new drugs and therapies.
Used in Research Settings:
In research settings, 5-Benzimidazolecarboxylic Acid, Hydrazide is utilized as a chemical compound for conducting various studies and experiments. Its use in this context is driven by the need to explore its properties, reactions, and potential applications in the field of pharmaceuticals and other related areas.

Upstream product

• 619-05-6 3,4-diaminobenzoic acid 
• 37466-90-3 ethyl 3,4-diaminobenzoate 
• 58842-61-8 ethyl benzimidazole-6-carboxylate 
• 26663-77-4 methyl 1H-benzo[d]imidazole-5-carboxylate 
• 15788-16-6 5-benzimidazolecarboxylic acid 
• 614-97-1 5-methylbenzimidazole 
• 58842-61-8 benzimidazole-5-carboxylic acid ethyl ester 

Downstream Products

• 606091-78-5 5-(1H-benzo[d]imidazol-6-yl)-1,3,4-oxadiazole-2-thiol 
• 1206789-73-2 N'-[(2-hydroxy-3,5-di-tert-butyl)phenylmethylene]-1H-benzo[d]imidazole-6-formhydrazide 
• 1333406-27-1 5-(5-((3,4-dimethoxyphenylsulfonyl)methyl)-1,3,4-thiadiazol-2-yl)benzimidazole 
• 1333406-26-0 5-(5-((3,4-dimethoxyphenylthio)methyl)-1,3,4-thiadiazol-2-yl)benzimidazole 
• 1333405-95-0 5-(5-(2,5-bis(trifluormethyl)phenylethyl)-1,3,4-oxadiazol-2-yl)benzimidazole 

Relevant articles and documents

Design and evaluation of Nrf2 activators with 1,3,4-oxa/thiadiazole core as neuro-protective agents against oxidative stress in PC-12 cells

Oxidative stress plays vital roles in virous neurodegenerative diseases including Alzheimer's disease. Activation of the transcription factor Nrf2 (nuclear factor erythroid 2-related factor 2), the key regulator of oxidative stress, may provide a new ther

Development of hydroxy-based sphingosine kinase inhibitors and anti-inflammation in dextran sodium sulfate induced colitis in mice

Sphingosine kinase (SphK)-catalyzed production of sphingosine-1-phosphate (S1P) regulates cell growth, survival and proliferation as well as inflammatory status in animals. In recent study we reported the N′-(3-(benzyloxy)benzylidene)-3,4,5-trihydroxybenzohydrazide scaffold as a potent SphK inhibitor. As a continuation of these efforts, 51 derivatives were synthesized and evaluated by SphK1/2 inhibitory activities for structure-activity relationship (SAR) study. Among them, 33 was identified as the most potent SphK inhibitor. Potency of 33 was also observed to efficiently decrease SphK1/2 expression in human colorectal cancer cells (HCT116) and significantly inhibit dextran sodium sulfate (DSS)-induced colitis as well as the decreased expression of interleukin (IL)-6 and cyclooxygenase-2 (COX-2) in mouse models. Collectively, 33 was validated as an effective SphK inhibitor, which can be served as anti-inflammatory agent to probably treat inflammatory bowel diseases in human.

SUBSTITUTED HYDRAZIDE COMPOUNDS AND APPLICATION THEREOF

The invention relates to substituted hydrazide compounds as shown by general formula I, including geometrical isomers, pharmaceutically acceptable salts, hydrates, solvates or prodrugs thereof, and use of the same, wherein the substitutents Ar and R having the same meanings as given in the Description. T The invention further relates to the use of compounds of general formula I in the preparation of medicament for the treatment and/or prevention of cancer and other proliferative diseases.